Vaccinations for rheumatoid arthritis

Marcia A. Friedman, Kevin Winthrop

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Rheumatoid arthritis (RA) patients experience increased infectious disease-related morbidity and mortality, and vaccinations represent an important element in their care. However, vaccine immunogenicity can be affected by disease-modifying antirheumatic drug (DMARD) therapy, such that vaccine choice and timing can be clinically challenging. We review the indications, safety, and immunogenicity of vaccines in the setting of RA. RECENT FINDINGS: Recent recommendations highlight the use of influenza, pneumococcal, and shingles vaccines in RA patients. Studies suggest influenza and pneumococcal vaccines are underutilized, but well tolerated in RA patients and generally immunogenic during DMARD use with the exception of rituximab. Though data for other nonlive vaccines are more limited, hepatitis B virus and human papilloma virus vaccines also appear well tolerated and immunogenic in this population. Live vaccines for shingles and yellow fever remain contraindicated in some RA patients; however, limited data suggest they might be well tolerated in certain individuals. SUMMARY: The review updates rheumatologists on the optimal use and timing of routine vaccinations in the care of RA.

Original languageEnglish (US)
JournalCurrent Opinion in Rheumatology
DOIs
StateAccepted/In press - Mar 16 2016

Fingerprint

Rheumatoid Arthritis
Vaccination
Pneumococcal Vaccines
Antirheumatic Agents
Influenza Vaccines
Vaccines
Herpes Zoster Vaccine
Yellow Fever Vaccine
Papillomavirus Vaccines
Hepatitis B virus
Communicable Diseases
Morbidity
Safety
Drug Therapy
Mortality
Population
Vaccine Immunogenicity

ASJC Scopus subject areas

  • Rheumatology

Cite this

Vaccinations for rheumatoid arthritis. / Friedman, Marcia A.; Winthrop, Kevin.

In: Current Opinion in Rheumatology, 16.03.2016.

Research output: Contribution to journalArticle

@article{b7792ce3b3a84017a1ae12dfd37f5ccf,
title = "Vaccinations for rheumatoid arthritis",
abstract = "PURPOSE OF REVIEW: Rheumatoid arthritis (RA) patients experience increased infectious disease-related morbidity and mortality, and vaccinations represent an important element in their care. However, vaccine immunogenicity can be affected by disease-modifying antirheumatic drug (DMARD) therapy, such that vaccine choice and timing can be clinically challenging. We review the indications, safety, and immunogenicity of vaccines in the setting of RA. RECENT FINDINGS: Recent recommendations highlight the use of influenza, pneumococcal, and shingles vaccines in RA patients. Studies suggest influenza and pneumococcal vaccines are underutilized, but well tolerated in RA patients and generally immunogenic during DMARD use with the exception of rituximab. Though data for other nonlive vaccines are more limited, hepatitis B virus and human papilloma virus vaccines also appear well tolerated and immunogenic in this population. Live vaccines for shingles and yellow fever remain contraindicated in some RA patients; however, limited data suggest they might be well tolerated in certain individuals. SUMMARY: The review updates rheumatologists on the optimal use and timing of routine vaccinations in the care of RA.",
author = "Friedman, {Marcia A.} and Kevin Winthrop",
year = "2016",
month = "3",
day = "16",
doi = "10.1097/BOR.0000000000000281",
language = "English (US)",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Vaccinations for rheumatoid arthritis

AU - Friedman, Marcia A.

AU - Winthrop, Kevin

PY - 2016/3/16

Y1 - 2016/3/16

N2 - PURPOSE OF REVIEW: Rheumatoid arthritis (RA) patients experience increased infectious disease-related morbidity and mortality, and vaccinations represent an important element in their care. However, vaccine immunogenicity can be affected by disease-modifying antirheumatic drug (DMARD) therapy, such that vaccine choice and timing can be clinically challenging. We review the indications, safety, and immunogenicity of vaccines in the setting of RA. RECENT FINDINGS: Recent recommendations highlight the use of influenza, pneumococcal, and shingles vaccines in RA patients. Studies suggest influenza and pneumococcal vaccines are underutilized, but well tolerated in RA patients and generally immunogenic during DMARD use with the exception of rituximab. Though data for other nonlive vaccines are more limited, hepatitis B virus and human papilloma virus vaccines also appear well tolerated and immunogenic in this population. Live vaccines for shingles and yellow fever remain contraindicated in some RA patients; however, limited data suggest they might be well tolerated in certain individuals. SUMMARY: The review updates rheumatologists on the optimal use and timing of routine vaccinations in the care of RA.

AB - PURPOSE OF REVIEW: Rheumatoid arthritis (RA) patients experience increased infectious disease-related morbidity and mortality, and vaccinations represent an important element in their care. However, vaccine immunogenicity can be affected by disease-modifying antirheumatic drug (DMARD) therapy, such that vaccine choice and timing can be clinically challenging. We review the indications, safety, and immunogenicity of vaccines in the setting of RA. RECENT FINDINGS: Recent recommendations highlight the use of influenza, pneumococcal, and shingles vaccines in RA patients. Studies suggest influenza and pneumococcal vaccines are underutilized, but well tolerated in RA patients and generally immunogenic during DMARD use with the exception of rituximab. Though data for other nonlive vaccines are more limited, hepatitis B virus and human papilloma virus vaccines also appear well tolerated and immunogenic in this population. Live vaccines for shingles and yellow fever remain contraindicated in some RA patients; however, limited data suggest they might be well tolerated in certain individuals. SUMMARY: The review updates rheumatologists on the optimal use and timing of routine vaccinations in the care of RA.

UR - http://www.scopus.com/inward/record.url?scp=84961226593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961226593&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000281

DO - 10.1097/BOR.0000000000000281

M3 - Article

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

ER -